antibodi
passiv
activ
immun
play
central
role
prophylaxi
mani
infecti
agent
neutral
primari
function
antibodi
protect
virus
rel
contribut
fcdepend
complementdepend
antivir
activ
antibodi
found
vari
differ
virus
recent
studi
multipl
hit
model
explain
antibodi
neutral
virus
recent
data
stoichiometri
antibodi
neutral
suggest
organ
viral
surfac
protein
virus
addit
viru
size
influenc
level
antibodi
occup
requir
neutral
new
find
improv
strategi
therapeut
antibodi
engin
ration
vaccin
design
tradit
activ
passiv
immun
larg
develop
trial
error
precis
mechan
immun
actual
work
often
highest
prioriti
compar
efficaci
manufactur
safeti
exampl
mechan
protect
offer
smallpox
vaccin
sinc
edward
jenner
cowpox
vaccin
develop
modern
day
vaccinia
vaccin
help
erad
smallpox
poorli
understood
recent
found
neutral
antibodi
nab
crucial
factor
protect
vaccin
role
antibodi
protect
support
technolog
engin
antibodi
fab
fc
portion
matur
review
seem
logic
return
basic
question
antibodi
protect
virus
although
numer
passiv
antibodi
protect
studi
differ
virus
use
differ
anim
model
conduct
seem
definit
answer
review
nevertheless
certain
gener
may
hold
true
case
antibodi
neutral
vitro
usual
protect
better
antibodi
neutral
ii
nonnab
may
protect
depend
fcmediat
effector
function
iii
f
ab
portion
nab
also
protect
although
activ
usual
less
potent
whole
igg
review
highlight
recent
studi
relev
understand
viru
neutral
antibodi
protect
signific
advanc
made
put
interact
antibodi
viru
condit
requir
neutral
spatial
context
furthermor
advanc
antibodi
engin
especi
fc
region
allow
research
distinguish
rel
import
antibodydepend
cellmedi
cytotox
adcc
complementdepend
cytotox
cdc
vivo
monkey
model
first
time
new
insight
ration
approach
vaccin
design
formul
discuss
primari
role
antibodi
prevent
infect
reduc
overal
viral
burden
host
extent
infect
contain
ensu
immun
respons
antibodymedi
protect
infecti
agent
base
direct
indirect
function
direct
function
antibodi
neutral
refer
abolit
pathogen
infect
upon
antibodi
bind
particip
compon
innat
adapt
immun
system
neutral
probabl
power
function
antibodi
exert
virus
demonstr
remov
fc
portion
interfer
protect
capac
antibodi
despit
decreas
halfliv
f
ab
fragment
fcmediat
protect
function
antibodi
gain
increas
attent
number
recent
studi
show
substanti
improv
potenc
nab
function
includ
activ
complement
cascad
result
lysi
pathogen
infect
cell
cdc
immun
complex
antibodyco
pathogen
activ
antigenpres
cell
via
fc
complement
receptor
result
uptak
process
antigen
present
adapt
immun
system
way
virus
remov
circul
phagocytosi
process
adapt
immun
system
prime
initi
acceler
time
effector
function
antibodi
depend
interact
fc
receptor
fcr
express
immun
cell
regul
combin
antibodi
isotyp
fcr
class
adcc
instanc
describ
lysi
antibodyflag
cell
natur
killer
nk
cell
trigger
signal
antibodi
bound
surfac
infect
cell
via
lowaffin
fcrgiiia
extent
effector
function
contribut
protect
appear
specif
differ
virus
gener
vitro
neutral
gener
correl
well
protect
vivo
except
ebola
viru
even
high
titer
nab
fail
protect
monkey
lethal
infect
complement
describ
import
antibodymedi
protect
sever
viral
infect
hiv
demonstr
neutral
monoclon
antibodi
mab
engin
activ
complement
protect
wildtyp
antibodi
howev
complement
fcr
bind
abolish
antibodi
show
reduc
vivo
protect
capac
moreov
complementmedi
virolysi
describ
acut
phase
infect
seem
impact
overal
cours
infect
clearli
indic
fcr
complement
bind
import
support
vivo
protect
capac
nab
taken
togeth
recent
data
demonstr
yet
learn
antibodi
effector
function
vivo
protect
differ
infecti
agent
knowledg
greatli
benefit
develop
therapeut
antibodi
optim
toward
specif
infecti
diseas
target
passiv
activ
immun
antibodi
occup
gener
mechan
viru
neutral
consid
neutral
share
mechan
antibodi
protect
virus
necessari
understand
molecular
basi
provid
use
insight
develop
passiv
antibodi
vaccin
two
propos
model
concern
stoichiometri
antibodi
neutral
virus
singl
hit
multipl
hit
model
hotli
debat
field
although
singl
hit
model
larg
refut
today
review
singl
hit
model
singl
antibodi
molecul
bind
crucial
site
viru
suffici
neutral
virion
multipl
hit
model
suggest
multipl
antibodi
molecul
requir
neutral
virion
model
explain
partli
steric
hindranc
caus
antibodi
occup
viral
surfac
restrict
viral
surfac
protein
su
nonenvelop
virus
eg
polioviru
envelop
virus
eg
hiv
interact
cellular
receptor
attach
cofactor
essenti
postattach
event
entri
review
multipl
hit
model
gain
recognit
sever
recent
studi
yang
et
al
suggest
neutral
would
necessari
occupi
everi
function
envelop
env
trimer
trimer
complex
heterodim
least
one
antibodi
molecul
given
averag
env
trimer
present
virion
theoret
would
requir
antibodi
molecul
neutral
virion
furthermor
group
also
show
viru
neutral
mediat
simpli
antibodi
bind
without
involv
function
crucial
site
su
propos
singl
hit
model
author
insert
foreign
flag
tag
function
unimport
region
differ
hiv
isol
found
antiflag
antibodi
neutral
differ
isol
equal
well
irrespect
natur
resist
antihiv
antibodi
support
antibodi
bindingoccup
princip
determin
viru
neutral
agreement
previou
studi
parallel
pierson
et
al
investig
stoichiometri
antibodi
neutral
west
nile
viru
wnv
also
found
wnv
neutral
multipl
hit
although
neutral
achiev
antibodi
bind
env
protein
present
virion
recent
stoichiometr
studi
provid
addit
insight
understand
viru
neutral
spatial
context
propos
extent
antibodi
coat
virion
surfac
number
antibodi
molecul
requir
neutral
appear
directli
proport
virion
size
virus
howev
antibodi
occup
viral
surfac
sole
factor
dictat
viru
neutral
intrigu
question
antibodi
molecul
requir
neutral
wnv
versu
antibodiesvirion
although
significantli
larger
wnv
versu
nm
diamet
discrep
may
explain
number
factor
concern
su
organ
virion
figur
wnv
flavivirus
su
pack
regularli
icosahedr
virion
therefor
level
antibodi
occup
requir
neutral
proport
viru
size
found
mani
virus
regularli
pack
su
eg
antibodi
molecul
requir
neutral
papillomaviru
slightli
bigger
flaviviru
review
su
env
trimer
complex
scatter
spars
viral
surfac
importantli
singl
function
hiv
env
trimer
suffici
mediat
viral
entri
comparison
influenza
viru
env
trimer
requir
addit
free
su
fluid
nonrigid
viral
membran
may
abl
float
away
area
occupi
bound
antibodi
consequ
neutral
requir
occup
everi
env
trimer
irrespect
viru
size
dens
pack
virion
exampl
wnv
steric
hindranc
antibodi
bind
may
extend
neighbor
su
therefor
level
antibodi
occup
requir
neutral
may
predict
viru
size
viral
exampl
viru
neutral
mediat
antibodi
occup
specif
infect
organ
su
vari
virus
therefor
may
appropri
consid
antibodi
occup
molecular
ratio
total
number
avail
factor
influenc
antibodi
neutral
virus
number
factor
structur
virus
antibodi
influenc
stoichiometri
neutral
antibodi
occup
densiti
su
pack
viral
surfac
determin
whether
steric
hindranc
due
bind
antibodi
su
complex
extend
neighbor
complex
high
antibodi
occup
requir
neutral
virus
low
su
densiti
ii
space
neutral
epitop
determin
antibodi
molecul
bind
multival
depend
su
space
antibodi
isotyp
antibodi
bind
one
su
low
antibodi
occup
may
suffici
neutral
iii
unoccupi
su
complex
envelop
virus
may
abl
move
later
reduc
steric
hindranc
caus
neighbor
antibodybound
spike
consequ
higher
degre
antibodi
occup
requir
neutral
compar
virus
rigid
su
organ
iv
certain
epitop
may
easili
access
antibodi
occlud
intramolecularli
intermolecularli
epitop
locat
recess
area
near
glycan
su
proxim
neighbor
su
viral
membran
usual
requir
higher
antibodi
concentr
achiev
neutral
occup
wellexpos
epitop
regard
antibodi
v
antibodi
isotyp
determin
valenc
spanwidth
flexibl
antibodi
vi
antibodi
affin
determin
effect
kinet
antibodi
bind
combin
viral
factor
outlin
overal
avid
antibodyviru
interact
antibodi
concentr
requir
achiev
neutral
occup
determin
abl
occupi
epitop
rather
antibodi
viru
size
overal
consid
basic
goal
passiv
activ
immun
administ
elicit
nab
adequ
avid
titer
ensur
suffici
occup
neutral
increas
knowledg
epitop
see
su
structur
su
organ
number
viru
particl
requir
product
transmissionrepl
differ
viral
diseas
may
possibl
deriv
mathemat
model
guid
formul
passiv
antibodi
preclin
clinic
trial
futur
although
antibodi
occup
high
affin
high
densiti
neutral
virus
effect
provid
protect
import
note
mani
domin
epitop
viral
su
prone
mutat
locat
insid
core
function
su
complex
unavail
antibodi
bind
review
antibodi
latter
epitop
presum
elicit
viral
debri
produc
infect
instanc
analysi
memori
b
cell
antibodi
respons
sar
coronaviru
infect
found
suspecif
antibodi
neutral
viru
also
isol
viral
su
use
immunogen
seem
typic
induc
larg
fraction
nonnab
review
certain
rna
virus
retrovirus
particular
develop
array
special
featur
su
exampl
hyperglycosyl
expos
face
hypermut
nonessenti
region
escap
nab
review
result
virus
exist
numer
antigen
serotyp
varieti
target
tradit
passiv
activ
immun
howev
area
su
refractori
mutat
due
function
constraint
exampl
receptor
bind
site
therefor
antibodi
epitop
overlap
area
import
su
function
usual
associ
neutral
activ
sever
strain
antibodi
known
broadli
nab
effort
maxim
potenc
breadth
antibodi
protect
highli
variabl
virus
isolatespecif
nonneutr
antibodi
gener
consid
effect
nab
target
conserv
epitop
current
unifi
system
definit
nab
breadth
import
clarifi
antibodi
broad
neutral
activ
necessarili
mean
nab
crossneutr
viral
genotyp
isol
nevertheless
assess
neutral
breadth
antibodi
recogn
key
issu
vaccin
develop
hiv
field
strategi
analysi
nab
respons
induc
immun
propos
import
question
mani
conserv
neutral
epitop
exist
differ
virus
epitop
arrang
viral
surfac
whether
arrang
su
would
allow
simultan
bind
antibodi
complementari
specif
thu
justifi
cost
develop
multipl
mab
junctur
mab
cocktail
formul
target
multipl
neutral
epitop
simultan
believ
reduc
risk
viru
escap
possibl
enhanc
neutral
synerg
recent
studi
mab
cocktail
sar
coronaviru
rabi
viru
rv
suggest
benefit
data
concern
effici
singl
mab
formul
signific
viru
escap
expect
use
palivizumab
broadli
neutral
human
mab
f
protein
respiratori
syncyti
viru
rsv
prophylaxi
sever
rsv
diseas
highrisk
infant
children
review
although
escap
virus
cell
cultur
anim
model
human
report
palivizumab
unclear
escap
mutant
pathogen
select
amplifi
human
popul
prolong
use
palivizumab
thu
reduc
valu
mab
crucial
follow
longterm
effect
palivizumab
circul
rsv
determin
mab
cocktail
requir
target
multipl
conserv
epitop
rsv
infecti
agent
current
trend
passiv
antibodi
develop
replac
polyclon
antibodi
pab
known
associ
number
manufactur
safeti
issu
see
singl
multipl
mab
anoth
area
interest
explor
whether
highli
potent
mab
use
tackl
infect
protect
pab
eg
hepat
c
ig
hcig
human
pab
product
use
postexposur
prophylaxi
rv
hepat
viru
hbv
prophylaxi
sever
ill
rsv
varicellazost
measl
viru
highrisk
individu
prevent
congenit
infect
hbv
pab
prepar
also
wide
use
organ
transplant
protect
organ
recipi
emerg
cytomegaloviru
infect
due
immunosuppress
protect
transplant
liver
recurr
hbv
anoth
use
pab
reduc
sever
side
effect
caus
vaccin
smallpox
although
pab
prepar
proven
effect
prevent
treat
viral
infect
human
origin
lead
batchtobatch
variat
impli
theoret
risk
transfer
unrecogn
pathogen
moreov
shortag
suitabl
hyperimmun
donor
batch
contamin
donor
later
found
posit
certain
pathogen
avail
limit
number
facil
licens
produc
immunoglobulin
prepar
lead
frequent
albeit
temporari
shortag
mani
pab
product
product
easili
scale
emerg
situat
polyclon
immunoglobulin
prepar
also
interfer
concomit
subsequ
vaccin
pathogen
exampl
case
rsv
transit
polyclon
rsvigiv
monoclon
human
palivizumab
favor
lack
interfer
childhood
vaccin
case
exampl
hbv
rv
passiv
immun
found
interfer
activ
immun
activ
passiv
immun
recommend
postexposur
prophylaxi
addit
advantag
improv
safeti
specif
activ
recombin
mab
also
engin
favor
abolish
certain
effector
function
modifi
increas
serum
halflif
case
third
gener
therapeut
antirsv
mab
numaxyt
coupl
pro
drug
gemtuzumab
ozogamicin
radioisotop
ibritumomab
tiuxetan
chelat
tositumomab
toxin
potenti
specif
activ
main
limit
mab
outlin
monospecif
may
cover
natur
circul
antigen
variant
pathogen
may
readili
select
antibodi
escap
variant
order
overcom
limit
singl
mab
prepar
cocktail
mab
current
pursu
mani
viral
diseas
includ
hbv
rv
sar
viru
taken
togeth
consider
make
like
pab
product
reason
market
replac
recombin
mab
cocktail
thereof
futur
howev
rare
applic
requir
broad
rang
specif
pab
may
still
favor
blend
mab
diseas
tradit
attempt
fail
provid
effect
vaccin
exampl
hiv
hcv
import
investig
whether
knowledgebas
approach
bring
new
hope
develop
vaccin
consider
amount
scientif
knowledg
requir
viru
neutral
antibodi
protect
structur
conserv
neutral
epitop
su
organ
unfold
recent
studi
allow
one
attempt
ration
approach
vaccin
develop
aim
induc
protect
antibodi
respons
figur
outlin
scheme
knowledgebas
vaccin
design
current
intens
research
hiv
research
commun
scientif
path
also
known
revers
vaccinolog
retrovaccinolog
includ
first
identifi
specif
antibodi
respons
respons
viru
neutral
protect
follow
defin
antibodi
therapeut
knowledgebas
vaccin
design
elicit
protect
antibodi
improv
vaccin
compon
induct
protect
antibodi
respons
one
first
defin
specif
magnitud
antibodi
respons
requir
protect
one
method
isol
mab
subject
develop
protect
antibodi
respons
infect
vaccin
identifi
mab
neutral
viru
vitro
protect
relev
anim
model
viru
challeng
passiv
transfer
experi
prefer
mab
recogn
multipl
conserv
neutral
determin
given
viru
next
step
defin
neutral
epitop
xray
crystallograph
cryoelectron
microscop
techniqu
recent
appli
dissect
neutral
epitop
structur
spatial
provid
import
insight
condit
requir
viru
neutral
inform
provid
templat
design
immunogen
favor
present
desir
neutral
epitop
major
gap
requir
scientif
breakthrough
precis
mechan
immunogen
handl
process
vivo
activ
specif
b
cell
produc
target
nab
candid
desir
antigen
properti
screen
immunogen
anim
model
confirm
immunogen
elicit
desir
antibodi
respons
protect
anim
viru
challeng
immunogen
produc
equival
better
humor
respons
without
side
effect
associ
tradit
vaccin
would
favor
candid
clinic
evalu
molecular
model
use
illustr
igg
protein
data
bank
pdb
entri
fab
fragment
complex
pdb
entri
structur
determin
viru
neutral
appli
molecularstructur
inform
design
mimic
epitop
focu
antibodi
respons
broadli
neutral
epitop
immun
hope
approach
overcom
limit
tradit
vaccin
protect
antibodi
function
combin
viru
neutral
effectormedi
destruct
virion
infect
cell
multipl
dimens
antivir
activ
antibodi
help
prevent
infect
lower
viral
burden
thu
reduc
cell
death
extrem
immunolog
reaction
clinic
symptom
summar
recent
studi
broaden
think
mechan
antibodi
protect
believ
help
field
refin
strategi
improv
passiv
antibodi
vaccin
develop
applic
multipl
advanc
techniqu
includ
xray
crystallographi
cryoem
structur
model
viral
su
pack
viral
surfac
determin
stoichiometri
antibodi
neutral
virus
increas
understand
molecular
basi
antibodi
neutral
virus
also
provid
addit
rational
select
neutral
epitop
target
passiv
antibodi
formul
mab
cocktail
evid
differ
pathogen
requir
differ
effector
function
antibodi
also
creat
new
opportun
engin
fc
fragment
passiv
antibodi
choic
adjuv
deliveri
method
vaccin
favor
induct
particular
antibodi
isotyp
focu
effect
effector
function
particular
viral
diseas
